Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing, and shareholders may be entitled to damages and corporate governance reforms. The firm is focusing on long-term TVTX stockholders, urging them to contact Justin Kuehn, Esq. to discuss their rights.

The investigation aims to determine if there were any violations of fiduciary duties or instances of self-dealing by the company's leadership. Shareholders who have held TVTX stock for an extended period are particularly encouraged to participate, as their involvement could contribute to potential corporate governance reforms. Kuehn Law emphasizes that the consultation and case are free, with no obligation to the investor, and the firm covers all case costs.

Key Details for Shareholders

Shareholders are advised to act promptly, as there may be limited time to enforce their rights. Kuehn Law highlights that shareholder participation is crucial for maintaining the integrity and fairness of financial markets. The firm operates on a contingency basis, ensuring no upfront costs for investor clients.

For additional information, shareholders can visit the Kuehn Law website dedicated to shareholder derivative litigation. The firm is headquartered at 53 Hill Street, Suite 605, Southampton, NY 11968. Attorney advertising notes that prior results do not guarantee similar outcomes.

Travere Therapeutics, Inc. granted inducement equity awards covering an aggregate of 41,600 shares of its common stock to six new employees on July 10, 2026. The grants, consisting of inducement stock options and inducement restricted stock units (RSUs), were made as an inducement material to the individuals entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

The Compensation Committee of the Board of Directors approved the awards, which are subject to the terms of Travere’s 2018 Equity Incentive Plan but were granted outside of it. The aggregate grants include inducement stock options to purchase 18,000 shares and inducement RSUs covering 23,600 shares.

Grant Details

The stock options have an exercise price of $56.59 per share, representing the closing price of Travere’s common stock on the grant date. These non-qualified stock options have a 10-year term and vest over four years. Vesting commences with 25% of the shares vesting on the one-year anniversary of the grant date, while the remaining 75% vest in equal monthly installments over the subsequent 36 months, subject to continued service.

The RSUs also vest over four years, with 25% of the shares vesting on each anniversary of the grant date. These vesting schedules are contingent upon the new employees maintaining their service relationship with Travere through the applicable vesting dates.

Breakdown of Awards